Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase 2 8Phase 1/2 5Phase 3 3Phase NA 2Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Prostatic Neoplasms 4Ovarian Neoplasms 4Pancreatic Neoplasms 3Sarcoma 2Hematopoietic and Lymphoid System Neoplasm 2Glioma 2Glioblastoma 2Brain Neoplasms 2Urogenital Neoplasms 1Stomach Neoplasms 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Resectable Pancreatic Carcinoma 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pelvic Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Liposarcoma, Myxoid 1Liposarcoma 1Fallopian Tube Neoplasms 1Endometrial Serous Adenocarcinoma 1Desmoplastic Small Round Cell Tumor 1Colorectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Nivolumab 9pembrolizumab 6Ipilimumab 5Magnetic Resonance Spectroscopy 3resiquimod 2encorafenib 2binimetinib 2aldesleukin 2Oncolytic Virotherapy 2MART-1 Antigen 2Interleukin-2 2Cyclophosphamide 2urelumab 1tremelimumab 1tetraethylpyrazine 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1relatlimab 1montanide ISA 51 1glucopyranosyl lipid-A 1fludarabine phosphate 1fludarabine 1durvalumab 1clevudine 1cemiplimab 1avelumab 1Specimen Handling 1Sentinel Lymph Node Biopsy 1S 28463 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Melanoma × Specimen Handling × Clear all
NCT04581382 2025-07-10

Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma

Mayo Clinic

Phase EARLY_PHASE1 Completed
18 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡